Showing 441 - 460 results of 1,182 for search '"liver disease"', query time: 0.08s Refine Results
  1. 441
  2. 442
  3. 443
  4. 444
  5. 445
  6. 446
  7. 447

    Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease by Xinyue Li, Xiaojuan Wu, Yumei Jia, Jing Fu, Lin Zhang, Tao Jiang, Jia Liu, Guang Wang

    Published 2021-01-01
    “…In this study, we aimed to verify plasma fibroblast growth factor 21 (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the effectiveness of liraglutide on reducing liver fat content and serum (FGF21) levels in those patients. …”
    Get full text
    Article
  8. 448

    Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway by Jiaxin Zhang, Haixia Du, Menglan Shen, Zhengqi Zhao, Xinmiao Ye

    Published 2020-01-01
    “…Kangtaizhi granule (KTZG) is a Chinese medicine compound prescription and has been proven to be effective in nonalcoholic fatty liver disease (NAFLD) treatment clinically. However, the underlying mechanisms under this efficacy are rather elusive. …”
    Get full text
    Article
  9. 449

    Chemogenomic Screening in a Patient‐Derived 3D Fatty Liver Disease Model Reveals the CHRM1‐TRPM8 Axis as a Novel Module for Targeted Intervention by Sonia Youhanna, Aurino M. Kemas, Shane C. Wright, Yi Zhong, Britta Klumpp, Kathrin Klein, Aikaterini Motso, Maurice Michel, Nicole Ziegler, Mingmei Shang, Pierre Sabatier, Aimo Kannt, Hongda Sheng, Nuria Oliva‐Vilarnau, Florian A. Büttner, Brinton Seashore‐Ludlow, Jonas Schreiner, Maike Windbergs, Martin Cornillet, Niklas K. Björkström, Andreas J. Hülsmeier, Thorsten Hornemann, Jesper V. Olsen, Yi Wang, Roberto Gramignoli, Michael Sundström, Volker M. Lauschke

    Published 2025-01-01
    “…Abstract Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of chronic liver disease with few therapeutic options. To narrow the translational gap in the development of pharmacological MASH treatments, a 3D liver model from primary human hepatocytes and non‐parenchymal cells derived from patients with histologically confirmed MASH was established. …”
    Get full text
    Article
  10. 450

    Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis by Nikolina Canová, Jana Šípková, Mahak Arora, Zuzana Pavlíková, Zuzana Pavlíková, Tomáš Kučera, Ondřej Šeda, Tijana Šopin, Tomáš Vacík, Ondřej Slanař

    Published 2025-02-01
    “…Therefore, this study aimed to investigate the effects of celastrol on the galaninergic system expression in the heart and liver of mice suffering from diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH).MethodsThe male mice C57BL/6J were fed a Western-type high-fat diet for 16 and 20 weeks to induce obesity and MASLD/MASH. …”
    Get full text
    Article
  11. 451

    The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet by Farzad Shidfar, Samaneh Sadat Bahrololumi, Saeid Doaei, Assieh Mohammadzadeh, Maryam Gholamalizadeh, Ali Mohammadimanesh

    Published 2018-01-01
    “…Coronary artery disease is the most common cause of death in the patients with nonalcoholic fatty liver disease (NAFLD). Studies have shown that there is a strong relation between the increase in the aminotransferase levels and fat accumulation in the liver with cardiovascular complications, independent of all aspects of the metabolic syndrome. …”
    Get full text
    Article
  12. 452
  13. 453
  14. 454
  15. 455
  16. 456
  17. 457

    Lipotoxicity and metabolic disorders at obesity by V. T. Ivashkin, M. V. Mayevskaya

    Published 2010-02-01
    Subjects: “…non-alcoholic fatty liver disease…”
    Get full text
    Article
  18. 458
  19. 459
  20. 460